Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived CD34+, CD133+, and mesenchymal stem cells (Stem Cells Arabia)
- Development stage
- Unknown
- Lead developer
- Stem Cells Arabia
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-testicular
01
Overview
This is an investigational autologous cell therapy developed by Stem Cells Arabia for the treatment of non-obstructive azoospermia (NOA). The therapy utilizes a purified mixture of CD34+, CD133+, and mesenchymal stem cells (MSCs) harvested from the patient's own bone marrow. These cells are injected directly into the seminiferous tubules and testicular tissue on the same day as harvest, without in vitro expansion, to minimize the risk of genetic alterations. The treatment aims to restore the microenvironment necessary for spermatogenesis, potentially leading to the production of mature spermatozoa in men who previously lacked them.
- Other names
- Stem Cell Transplantation for Non-Obstructive AzoospermiaIntra-Testicular Transplantation of Purified Autologous Clusters of Differentiation (CD) 34+, 133+, and Mesenchymal Stem Cells
Beyond the preview
Go deeper on autologous bone marrow-derived CD34+, CD133+, and mesenchymal stem cells (Stem Cells Arabia).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived CD34+, CD133+, and mesenchymal stem cells (Stem Cells Arabia).